[Pharmacokinetic studies of the propolis constituent pinocembrin in the rat (author's transl)].
The present investigation into the pharmacokinetic behaviour of the propolis constituent pinocembrin which produces a relatively good antimicrobial effect in vitro, points to possible causes of its therapeutical failure when mice infected with Candida albicans were used as a model. The biological half-life periods for the phases of invasion and elimination were 26 and 268 min, respectively. The biological availability was 25%. Almost 15% of pinocembrin are excreted unchanged in faeces and urine. Even in case of oral application of doses of up to 500 mg/kg, the serum pinocembrin concentrations did not equal the MIC (minimal inhibitor concentration) values required in vitro. A considerable first-pass effect and accelerated processes of elimination are discussed as possible causes. It appears from the present findings that pinocembrin may be utilizable only for the external treatment of stomatomycoses.
D000818:Animals; D001711:Biotransformation; D002177:Candidiasis / Q000188:drug therapy; D005243:Feces / Q000032:analysis; D006207:Half-Life; D007700:Kinetics; D008297:Male; D011429:Propolis / Q000378:metabolism* / Q000627:therapeutic use; D051381:Rats; D012116:Resins, Plant / Q000378:metabolism*
D012116:Resins, Plant; D011429:Propolis
Pharmakokinetische Untersuchungen des Propolisinhaltsstoffes Pinocembrin an der Ratte.